NTT: World’s First Successful 1.4-Tbit/s Wireless Transmission in the Sub-THz Band
17.5.2023 11:09:00 EEST | Business Wire | Press release
Aiming to implement terabit-class wireless transmission to support wireless demand in the 2030s, NTT Corporation (NTT) has successfully achieved the world’s first “orbital angular momentum (OAM) multiplexing high-capacity wireless transmission—at 1.44 Tbit/s—using an ultra-wide bandwidth of 32 GHz. As an innovative wireless-communication technology that uses the sub-terahertz (sub-THz) band, this achievement will enable wireless access to vast amounts of information at data-transfer rate exceeding 1 Tbit/s. This achievement was realized using the sub-THz band within the range from 135 GHz to 170 GHz, and is an innovative wireless communication technology that enables wireless access to a huge amount of information exceeding 1 Tbit/s. As a key element of the “Innovative Optical and Wireless Network” (IOWN), which we aim to implement with our global partners, it is an extension of the high-capacity communication network and information-processing infrastructure centered on light to wireless networks including 6G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006084/en/
Figure 1: Image of OAM-multiplexing transmission technology and trends in high-capacity wireless transmission (Graphic: Business Wire)
Aiming to support the high-capacity network and information processing infrastructure of the IOWN and 6G and prepare for the increasing future demand for wireless communications, NTT is engaged in research and development with the goal of achieving terabit-class wireless transmission. To enhance the capacity of wireless communications, NTT is increasing the spatial multiplexing order by applying on a new principle using radio waves with “orbital angular momentum” (Figure 1) to increase wireless-transmission capacity and using the sub-terahertz (sub-THz) band to increase transmission bandwidth.
The approach taken by NTT is to use an analog circuit called a “Butler matrix” to increase the spatial multiplexing order by multiplexing multiple OAM waves. This approach reduces the enormous amount of digital signal processing required to eliminate interference between multiplexed data streams in high-capacity communications exceeding one terabit.
In this research, NTT has promoted research and development of sub-THz-band waveguide technology and succeeded in developing an antenna-integrated Butler matrix that operates with a wide bandwidth and low loss. The antenna-integrated Butler matrix is designed to simultaneously generate and separate eight different OAM waves over a very wide bandwidth, i.e., 135 to 170 GHz, which can be used to multiplex and transmit eight data signals. Moreover, by performing OAM multiplexing transmission with two different polarizations, it is possible to multiplex and transmit twice as many data signals simultaneously without them interfering. We conducted transmission tests using the antenna-integrated Butler matrix, and we achieved the world’s first successful large-capacity wireless transmission totaling 1.44 Tbit/s in the sub-THz bands of 135.5 to 151.5 GHz and 152.5 to 168.5 GHz (Figure 2). This transmission capacity is equivalent to the speed of simultaneous transmission of approximately 35,000 ultra-high-definition 4K videos (at about 40 Mbit/s) that can be available on current video websites. This speed enables the simultaneous transmission of 140 or more uncompressed 4K videos (at about 10 Gbit/s) for applications that require ultra-low latency.
This technology is expected to enable (i) broadband and high-speed wireless transmission comparable to optical transmission systems and (ii) seamless connection between wireless and optical transmission systems without the need for a complex digital signal-processing system for spatial multiplexing, since the analog circuit (i.e., the Butler matrix) handles the multiplexing of OAM waves. The next step in this development is to conduct demonstrations over longer distances (exceeding 100 m) while envisioning various applications of this technology in the real world, including wireless backhaul/fronthaul between base stations and relay transmission (Figure 3). We expect the eventual development of this technology to support the creation and spread of various future services, such as VR/AR (virtual reality/augmented reality), high-definition video transmission, connected cars, and telemedicine, as innovative wireless-communication technology in the IOWN and 6G era.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006084/en/
Contact information
[Media Contact]
NTT Corporation,
Science and Core Technology Laboratory Group,
nttrd-pr@ml.ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
